File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Monoclonal antibodies as targeting and therapeutic agents: Prospects for liver transplantation, hepatitis and hepatocellular carcinoma

TitleMonoclonal antibodies as targeting and therapeutic agents: Prospects for liver transplantation, hepatitis and hepatocellular carcinoma
Authors
KeywordsAntibody engineering
Hepatitis
Hepatocellular carcinoma
Monoclonal antibody
Single-chain antibody (scFv)
Therapeutics
Transplantation
Issue Date2006
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEP
Citation
Clinical And Experimental Pharmacology And Physiology, 2006, v. 33 n. 5-6, p. 482-488 How to Cite?
Abstract1. Monoclonal antibodies (mAbs) of high specificity and stability have become key resources in the therapeutic, diagnostic and drug discovery fields to treat various immunological disorders and malignancies of different organs. 2. The latest genetic engineering technology applied in antibody design and production, such as phage display technology and genetically modified mouse, have revolutionized the clinical applicability and feasibility of the use of mAbs in humans. 3. Innovative antibody products in the forms of single-chain or super-humanized antibody therapeutics having a higher affinity for target antigens and minimal antigenicity in hosts have been introduced for experimental purposes and/or clinical trials. 4. Although there are successful examples of antibody therapeutics in the market, the use of mAbs in treating hepatitis-related disease and hepatocellular carcinoma is rare and remains to be exploited. © 2006 Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/84000
ISSN
2012 Impact Factor: 2.16
2015 SCImago Journal Rankings: 0.944
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLuk, JMen_HK
dc.contributor.authorWong, KFen_HK
dc.date.accessioned2010-09-06T08:47:44Z-
dc.date.available2010-09-06T08:47:44Z-
dc.date.issued2006en_HK
dc.identifier.citationClinical And Experimental Pharmacology And Physiology, 2006, v. 33 n. 5-6, p. 482-488en_HK
dc.identifier.issn0305-1870en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84000-
dc.description.abstract1. Monoclonal antibodies (mAbs) of high specificity and stability have become key resources in the therapeutic, diagnostic and drug discovery fields to treat various immunological disorders and malignancies of different organs. 2. The latest genetic engineering technology applied in antibody design and production, such as phage display technology and genetically modified mouse, have revolutionized the clinical applicability and feasibility of the use of mAbs in humans. 3. Innovative antibody products in the forms of single-chain or super-humanized antibody therapeutics having a higher affinity for target antigens and minimal antigenicity in hosts have been introduced for experimental purposes and/or clinical trials. 4. Although there are successful examples of antibody therapeutics in the market, the use of mAbs in treating hepatitis-related disease and hepatocellular carcinoma is rare and remains to be exploited. © 2006 Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEPen_HK
dc.relation.ispartofClinical and Experimental Pharmacology and Physiologyen_HK
dc.subjectAntibody engineeringen_HK
dc.subjectHepatitisen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectMonoclonal antibodyen_HK
dc.subjectSingle-chain antibody (scFv)en_HK
dc.subjectTherapeuticsen_HK
dc.subjectTransplantationen_HK
dc.titleMonoclonal antibodies as targeting and therapeutic agents: Prospects for liver transplantation, hepatitis and hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0305-1870&volume=33 &issue=5-6&spage=482&epage=488&date=2006&atitle=Monoclonal+antibodies+as+targeting+and+therapeutic+agents:+prospects+for+liver+transplantation,+hepatitis+and+hepatocellular+carcinomaen_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1681.2006.04396.xen_HK
dc.identifier.pmid16700883-
dc.identifier.scopuseid_2-s2.0-33745202854en_HK
dc.identifier.hkuros118795en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745202854&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume33en_HK
dc.identifier.issue5-6en_HK
dc.identifier.spage482en_HK
dc.identifier.epage488en_HK
dc.identifier.isiWOS:000237420800012-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.scopusauthoridWong, KF=35081410800en_HK
dc.identifier.citeulike622413-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats